Scarica l'app Stockscreener
3.91
1.01%
-0.04
Pre-mercato:
3.90
-0.01
-0.26%
Precedente Chiudi:
$3.95
Aprire:
$4
Volume 24 ore:
1.01M
Relative Volume:
4.04
Capitalizzazione di mercato:
$494.87M
Reddito:
-
Utile/perdita netta:
$-59.00M
Rapporto P/E:
-8.3672
EPS:
-0.4673
Flusso di cassa netto:
$-51.97M
1 W Prestazione:
+42.70%
1M Prestazione:
+35.29%
6M Prestazione:
+375.61%
1 anno Prestazione:
+324.82%
Intervallo 1D:
$3.7621
$4.3101
Intervallo di 1 settimana:
$2.625
$4.3101
Portata 52W:
$0.62
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Nome
Nautilus Biotechnology Inc
Settore
Industria
Telefono
206-333-2001
Indirizzo
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
3.91 | 499.93M | 0 | -59.00M | -51.97M | -0.4673 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-05 | Downgrade | Goldman | Neutral → Sell |
| 2024-06-27 | Iniziato | Guggenheim | Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2022-01-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-02 | Iniziato | Cowen | Outperform |
| 2021-08-04 | Iniziato | Goldman | Neutral |
| 2021-07-13 | Iniziato | Jefferies | Buy |
Mostra tutto
Nautilus Biotechnology Inc Borsa (NAUT) Ultime notizie
Nautilus Biotechnology Unveils Voyager Proteomics Platform, Targets Beta Access in 2H and Launch Next Year - Yahoo Finance
Nautilus Biotechnology (NASDAQ:NAUT) Sets New 52-Week HighWhat's Next? - MarketBeat
Nautilus Biotechnology And 2 Other Compelling Penny Stocks For Your Watchlist - Yahoo Finance
Aug Chart Watch: Is Nautilus Biotechnology Inc forming a breakout patternTrade Entry Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference - Bitget
Nautilus management presents online March 25; webcast stays available - Stock Titan
Technical Analysis: Is Nautilus Biotechnology Inc stock a smart retirement pick2026 Earnings & Comprehensive Market Scan Insights - baoquankhu1.vn
If You Invested $1,000 in Nautilus Biotechnology Inc (NAUT) - Stock Titan
Published on: 2026-03-21 20:59:37 - baoquankhu1.vn
Baylor College of Medicine initiates research with Nautilus Biotechnology Voyager Platform - Traders Union
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform - Bitget
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program ... - Bluefield Daily Telegraph
NIH backs Baylor, Nautilus project to map cancer-driving proteins - Stock Titan
What’s the MACD signal for Nautilus Biotechnology Inc.July 2025 Chart Watch & High Win Rate Trade Tips - mfd.ru
Aug Sectors: Is Nautilus Biotechnology Inc forming a breakout patternWeekly Investment Summary & Daily Chart Pattern Signals - baoquankhu1.vn
Nautilus names Amber Faust VP of sales - The Pharma Letter
Sujal Patel Buys 25,000 Shares of Nautilus Biotechnology (NASDAQ:NAUT) Stock - MarketBeat
Executive Parag Mallick receives 280,000 stock options at Nautilus (NAUT) - Stock Titan
Nautilus (NAUT) CEO Sujal Patel receives 650,000 stock option award - Stock Titan
Nautilus Biotechnology (NAUT) Chief People Officer granted 160,000 options - Stock Titan
Nautilus (NAUT) General Counsel receives 160,000-share stock option grant - Stock Titan
Nautilus Biotechnology appoints Amber Faust as VP of sales By Investing.com - Investing.com Canada
Nautilus Biotechnology names Amber Faust as Vice President of Sales to drive proteomics expansion - Traders Union
NAUT: New proteomics platform promises comprehensive, reproducible protein analysis with broad applications - TradingView
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales - BioSpace
Nautilus Biotechnology appoints proteomics commercial leader Amber Faust as vice president of sales - marketscreener.com
Nautilus Biotechnology appoints Amber Faust as VP of sales - Investing.com
Sales veteran joins Nautilus to push single-molecule proteomics into labs - Stock Titan
Guggenheim Forecasts Strong Price Appreciation for Nautilus Biotechnology (NASDAQ:NAUT) Stock - Defense World
Aug Big Picture: What are PROFs growth levers2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
NAUT Should I Buy - Intellectia AI
Nautilus Biotechnology (NAUT) Target Price Raised by Guggenheim - GuruFocus
Nautilus debuts Voyager platform in push toward next-gen proteomics - Longevity.Technology
Nautilus Biotechnology (NASDAQ:NAUT) Price Target Raised to $4.00 at Guggenheim - MarketBeat
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology stock price target raised to $4 by Guggenheim - Investing.com Canada
Nautilus (NAUT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Nautilus Biotechnology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Nautilus Biotechnology Q4 Earnings Call Highlights - MarketBeat
Nautilus projects 15%-20% expense growth in 2026 as early access program ramps up - MSN
Nautilus Biotechnology (NASDAQ:NAUT) Announces Earnings Results - MarketBeat
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results - Investing News Network
Earnings call transcript: Nautilus Biotechnology Q4 2025 shows cost cuts By Investing.com - Investing.com Australia
Earnings call transcript: Nautilus Biotechnology Q4 2025 shows cost cuts - Investing.com
BRIEF-Nautilus Biotechnology Q4 EPS USD -0.11 - TradingView
Nautilus Biotechnology Inc. recently stated that the company does not expect to generate substantial revenue from early access program collaborations before 2026. - Bitget
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Market Fear: Whats the RSI of Nautilus Biotechnology Inc stockMarket Risk Report & Capital Protection Trade Alerts - baoquankhu1.vn
Nautilus Biotechnology (NAUT) trims 2025 loss, sees cash runway through 2027 - Stock Titan
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026 - BioSpace
Nautilus Biotechnology IncCommercial launch of Voyager platform expected in late 2026 - marketscreener.com
Nautilus Biotechnology Inc Azioni (NAUT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):